TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03374891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational video and/or handout
Description: The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
Study: NCT02040298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clemastine
Description: 4mg tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clemastine
Description: 4mg tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study: NCT01308489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo posterior spinal tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo anterior and posterior spinal tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03580200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling
Description: For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
Study: NCT00824967

Intervention type: OTHER
Group type: OTHER
Intervention: Training and valuation of the treating personnel
Description: Training and valuation of the treating personnel
Study: NCT00122070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Dosage can vary from 50 to 150 mg at PI's discretion
Study: NCT00948194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
Study: NCT00410514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02853786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA and advice
Description: Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LENA without advice
Description: Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
Study: NCT03734770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Progesterone
Description: Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
Study: NCT02269904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil Implants
Description: Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xelox regimes
Description: Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xelox regimes
Description: Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
Study: NCT01012037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin low dose
Description: patient to receive tablets containing low dose linagliptin twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patient to receive placebo tablet(s) matching linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin medium dose
Description: patient to receive a tablet containing medium dose linagliptin once daily
Study: NCT02186535

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D and Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D and Calcium
Study: NCT02617706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
Study: NCT04506385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
Study: NCT02918721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lidocaine
Description: Intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study: NCT02462122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Lotion
Study: NCT05387135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
Study: NCT04395989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Pyrotinib with nab-paclitaxel
Description: A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2: nab-paclitaxel
Description: A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: everolimus with nab-paclitaxel
Description: B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2: nab-paclitaxel
Description: B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1: PD-1 with nab-paclitaxel and famitinib
Description: C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2: nab-paclitaxel
Description: C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
Description: D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2: nab-paclitaxel, with maintenance of capecitabine
Description: D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
Study: NCT02928250

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: Patients in intervention group received carnosine capsules orally daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
Study: NCT04694014

Intervention type: BEHAVIORAL
Intervention: EI Open ended Pre-Survey and Semi Structured Interview
Description: Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant

Intervention type: BEHAVIORAL
Intervention: Behavioral and Cognitive Assessment
Description: Use Predictive index for both cognitive and behavioral assessment of the paticipants

Intervention type: BEHAVIORAL
Intervention: Geneva Emotional Competence Test (GECO)
Description: Administer the Geneva Emotional Competence Test to each participant
Study: NCT03273894

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation testing
Description: * body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C).
Study: NCT04395989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1: everolimus with nab-paclitaxel
Description: E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2: nab-paclitaxel
Description: E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
Study: NCT04850885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
Description: The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
Description: The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
Study: NCT03479658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: School-based nutritional education on healthy dietary habits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: School-based nutritional education on healthy dietary habits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional education
Description: School-based nutritional education on healthy dietary habits
Study: NCT03580486

Intervention type: OTHER
Intervention: The squares test
Description: The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.

Intervention type: OTHER
Intervention: The squares test
Description: The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
Study: NCT04708574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control
Study: NCT04321330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Study: NCT01879163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313
Description: Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A-IMX313
Description: Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A
Description: Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
Study: NCT02074618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise.
Description: Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
Study: NCT03787901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morula Vitrification
Description: Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
Study: NCT03924518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Hydrochloride
Description: Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo（Normal saline）
Description: therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Study: NCT02598687

Intervention type: DRUG
Group type: OTHER
Intervention: TH-302
Description: TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)

Intervention type: OTHER
Group type: OTHER
Intervention: HX4 scan
Description: HX 4 scan day 1 and day 8

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: 2mg/ml/min

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 50 mg/m2

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 23 x 1.8 Gy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
Study: NCT02458287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab 150mg
Description: Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
Study: NCT03787901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morula Vitrification
Description: Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
Study: NCT03042585

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: When radiation is given in a way to cover the whole body, it is called total body irradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: When radiation is given in a way to cover the whole body, it is called total body irradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: When radiation is given in a way to cover the whole body, it is called total body irradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: When radiation is given in a way to cover the whole body, it is called total body irradiation.
Study: NCT02255955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium and 30mg codeine
Description: Postoperative contramal consumption, pain intensity, side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg paracetamol and 30 mg codeine
Description: Postoperative contramal consumption, pain intensity, side effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: Postoperative contramal consumption, pain intensity, side effects